Fluid Biomed, a clinical-stage medical device company specializing in vascular disease treatments, has announced the successful closure of a USD $27 million Series A equity financing round.
The oversubscribed round was co-led by Amplitude Ventures and an undisclosed strategic partner, with additional investment from IAG Capital Partners, LifeArc Ventures, and returning backers ShangBay Capital and METIS Innovative.
The funding will support the development and expanded clinical trials of the ReSolv™ stent, a groundbreaking bioabsorbable polymer-based stent designed to treat brain aneurysms.
Developed by co-founders Dr. John Wong and Dr. Alim Mitha—both academic neurosurgeons at the University of Calgary—the stent represents a major leap forward in medical technology for addressing one of the leading causes of stroke and disability.
Brain aneurysms affect 6.7 million people in the U.S. alone, with more than 30,000 rupturing each year, often resulting in severe disability or death. Fluid Biomed’s ReSolv™ stent, validated by years of research and an initial human clinical study, offers a promising solution. Unlike traditional metallic stents, ReSolv™ is designed to bioabsorb into the body, reducing long-term risks and improving patient outcomes.
“This financing brings together international investors with unparalleled expertise to accelerate our progress,” said Dr. Wong, Fluid Biomed’s CEO. “It will enable us to make lifesaving devices available sooner to patients and physicians worldwide.”
Dr. Mitha, the company’s president and CTO, highlighted the impact of the funding on future innovation: “This capital will allow us to scale up clinical trials and expand our product pipeline, solidifying our position as a leader in neurovascular treatment.”
Jean-Francois Pariseau, co-founder and partner at Amplitude Ventures, emphasized the significance of the investment. “Fluid Biomed’s ReSolv™ stent has remarkable potential to transform patient care,” he said. “The founders’ extensive expertise in neuroscience and innovation has led to the creation of a truly novel technology with global implications.”
Fluid Biomed’s ReSolv™ stent is the world’s first bioabsorbable neurovascular stent designed specifically for brain aneurysms. With the additional funding, the Calgary-based company plans to conduct larger patient studies and broaden its pipeline of vascular treatments.
By combining cutting-edge research with clinical expertise, Fluid Biomed is poised to revolutionize the treatment of brain aneurysms and improve outcomes for millions of patients worldwide.
Leave a Reply